MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.28
-0.29
-1.99%
After Hours: 14.45 +0.17 +1.19% 18:24 05/22 EDT
OPEN
14.57
PREV CLOSE
14.57
HIGH
14.87
LOW
14.27
VOLUME
935.92K
TURNOVER
--
52 WEEK HIGH
14.87
52 WEEK LOW
4.010
MARKET CAP
560.05M
P/E (TTM)
-8.1414
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NERV stock price target is 19.40 with a high estimate of 23.00 and a low estimate of 18.00.

EPS

NERV News

More
Edited Transcript of NERV earnings conference call or presentation 4-May-20 12:30pm GMT
Q1 2020 Minerva Neurosciences Inc Earnings Call
Thomson Reuters StreetEvents · 3h ago
Stocks That Hit 52-Week Highs On Friday
On Friday, 46 stocks hit new 52-week highs.
Benzinga · 3d ago
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 6d ago
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 120 stocks hit new 52-week highs.
Benzinga · 05/18 14:44
Stocks That Hit 52-Week Highs On Wednesday
This morning 35 companies set new 52-week highs.
Benzinga · 05/13 14:35
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
Stocks That Hit 52-Week Highs On Tuesday
Tuesday morning saw 85 companies set new 52-week highs.
Benzinga · 05/12 14:41
Top Ranked Momentum Stocks to Buy for May 11th
Zacks · 05/11 14:52

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About NERV

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
More

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.